RE:RE:RE:ProthenaUh... the amyloid oligomers come from the amyloid plaques. Removing the plaques, which is what Aducanumab/ Aduhelm does, also removes oligomers as a danger to cells. And that's the reason behind Prothena's statement.
Removing only the oligomers and letting the plaques remain still lets (newer) oligomers cause problems for cells. Maybe that's the reason why PMN is not getting attention from large cap pharma corporations.
You should look up Dennis Selkoe's explanation of this. (Hopefully you know who Selkoe is.)